PeptiDream in discovery deal with GSK

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) partnered with PeptiDream Inc. (Tokyo, Japan) to discover and develop peptide therapeutics against the pharma's targets using the biotech's Peptide Discovery Platform System (PDPS). PDPS enables incorporation of modified unnatural amino acids into mRNA display peptide libraries. This includes the incorporation of N-methylation, a modification that increases a peptide's ability to permeate cells. The companies would not disclose details of the deal. ...